Total Payments
$2,674
2024 Payments
$61.40
Companies
24
Transactions
156
Medicare Patients
1,493
Medicare Billing
$230,293
Payment Breakdown by Category
Food & Beverage$2,674 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,674 | 156 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $692.11 | 35 | $0 (2023) |
| Novo Nordisk Inc | $341.42 | 19 | $0 (2024) |
| Lilly USA, LLC | $221.84 | 14 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $184.98 | 13 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $176.85 | 12 | $0 (2022) |
| Abbott Laboratories | $144.71 | 9 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $141.76 | 2 | $0 (2021) |
| Amgen Inc. | $140.40 | 9 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $102.17 | 7 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $71.03 | 4 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61.40 | 3 | Abbott Laboratories ($38.22) |
| 2023 | $263.15 | 15 | AbbVie Inc. ($97.93) |
| 2022 | $691.73 | 42 | ABBVIE INC. ($206.40) |
| 2021 | $1,584 | 91 | AbbVie Inc. ($387.78) |
| 2020 | $74.21 | 5 | Lilly USA, LLC ($20.42) |
All Payment Transactions
156 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Diabetes Care | ||||||
| 12/19/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Diabetes Care | ||||||
| 12/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: Diabetes | ||||||
| 05/09/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Obesity | ||||||
| 04/12/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: NEUROSCIENCE | ||||||
| 04/12/2023 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Diabetes | ||||||
| 04/10/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/28/2023 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, PAXLOVID | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: VACCINES | ||||||
| 03/20/2023 | Abbott Laboratories | FREESTYLE LIBRE 2 (Device) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Diabetes Care | ||||||
| 03/15/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/28/2023 | AbbVie Inc. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: IMMUNOLOGY | ||||||
| 02/13/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: Oncology | ||||||
| 02/09/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: Obesity | ||||||
| 02/08/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: NEUROSCIENCE | ||||||
| 02/01/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Inflammation | ||||||
| 01/31/2023 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Diabetes | ||||||
| 01/12/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: NEUROSCIENCE | ||||||
| 01/11/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: NEUROSCIENCE | ||||||
| 12/27/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: Diabetes Care | ||||||
| 12/16/2022 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: VACCINES | ||||||
| 11/16/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: NEUROSCIENCE | ||||||
| 11/14/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $12.88 | General |
| Category: NEUROSCIENCE | ||||||
| 11/03/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Diabetes Care | ||||||
| 10/10/2022 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: Inflammation | ||||||
| 10/09/2022 | Abbott Laboratories | FREESTYLE LIBRE 2 (Device) | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: Diabetes Care | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 443 | 1,042 | $231,938 | $91,772 |
| 2022 | 4 | 425 | 764 | $179,466 | $70,776 |
| 2021 | 7 | 292 | 463 | $101,226 | $43,698 |
| 2020 | 4 | 333 | 467 | $82,363 | $24,047 |
Total Patients
1,493
Total Services
2,736
Medicare Billing
$230,293
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 333 | 932 | $198,516 | $80,395 | 40.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 96 | 96 | $31,392 | $10,391 | 33.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 14 | $2,030 | $986.70 | 48.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 242 | 573 | $122,049 | $51,490 | 42.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 157 | 157 | $51,339 | $16,930 | 33.0% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 15 | 23 | $3,174 | $1,243 | 39.2% |
| 99305 | Initial nursing facility visit per day, typically 35 minutes | Facility | 2022 | 11 | 11 | $2,904 | $1,112 | 38.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 122 | 286 | $60,918 | $28,460 | 46.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 82 | 82 | $26,814 | $9,502 | 35.4% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 31 | 37 | $5,106 | $2,017 | 39.5% |
| 99305 | Initial nursing facility visit, typically 35 minutes per day | Facility | 2021 | 15 | 15 | $3,960 | $1,534 | 38.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 13 | 14 | $2,030 | $1,019 | 50.2% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 14 | 14 | $1,708 | $913.64 | 53.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 15 | 15 | $690.00 | $252.00 | 36.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 189 | 298 | $64,934 | $16,326 | 25.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 55 | 55 | $11,165 | $6,278 | 56.2% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 77 | 101 | $4,343 | $970.07 | 22.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 12 | 13 | $1,921 | $472.96 | 24.6% |
About Dr. Gary Vickers, DO
Dr. Gary Vickers, DO is a Hospitalist healthcare provider based in Chesterfield, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902867633.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Vickers, DO has received a total of $2,674 in payments from pharmaceutical and medical device companies, with $61.40 received in 2024. These payments were reported across 156 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($2,674).
As a Medicare-enrolled provider, Vickers has provided services to 1,493 Medicare beneficiaries, totaling 2,736 services with total Medicare billing of $230,293. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospitalist
- Other Specialties Family Medicine
- Location Chesterfield, MO
- Active Since 03/31/2006
- Last Updated 01/25/2021
- Taxonomy Code 208M00000X
- Entity Type Individual
- NPI Number 1902867633
Products in Payments
- UBRELVY (Drug) $273.00
- Ozempic (Drug) $200.98
- XARELTO (Drug) $176.85
- QULIPTA (Drug) $142.70
- LINZESS (Drug) $142.36
- NURTEC ODT (Drug) $141.76
- FARXIGA (Drug) $99.37
- BREZTRI (Drug) $85.61
- VRAYLAR (Drug) $84.69
- Saxenda (Drug) $81.05
- BAQSIMI (Drug) $77.19
- BELSOMRA (Drug) $73.34
- GEMTESA (Drug) $71.03
- Vascepa (Drug) $70.93
- Aimovig (Biological) $70.54
- TRULICITY (Drug) $67.80
- CONTRAVE (Drug) $66.58
- Otezla (Drug) $54.78
- Livalo (Drug) $49.08
- Dayvigo (Drug) $45.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.